INTERNATIONAL JOURNAL OF CANCER-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0 偏重的研究方向：临床试验 经验分享：2024..9.5投 9.10under review 至今还在UR 都说这个杂志速度快 看了一圈没一个人比我久的我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：分享一下我的投稿经历 2020.5.9 submitted to the journal 2020.5.11 under evaluation 2020.5.11 under review 2020.6.7 Awaiting descision 2020.6.11 Major revision 2020.8.10 Revision submitted 2020.8.10 under evaluation 2020.8.13 under review 2020.9.5 Awaiting descision 2020.9.9 Accepted 首次投IJC，投的综述，他们的综述一般是约稿，但是也收散稿，我是提前和编辑部发了邮件自荐的，杂志主编看了后很感兴趣，希望我投稿。审稿人虽然是匿名，但是从comments的言辞之间，让我感觉是其中的一位业界大牛Angelika Amon （Koch Institute MIT）。读了她的意见真是醍醐灌顶，受益良多。所以大修之后基本上改的面目全非，但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床 经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=278, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2200790, encodeId=b1a72200e9029, content=投过3次，第一次18天一审回来，中，快接收时候要实验原始数据第二次under consideration 5天后秒拒第三次 3个月一审回来，中，一开始under consideration 9天后要求改格式并上传实验原始数据，然后才送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b65125344, createdName=146449eem63暂无昵称, createdTime=Sat Apr 27 23:06:31 CST 2024, time=2024-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2180835, encodeId=b19b21808352d, content=求问各位大佬，Under evaluation已经12天了，可以催稿么？着急毕业。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=257, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2029080835, createdName=ms6000000445449810, createdTime=Thu Jan 11 20:03:35 CST 2024, time=2024-01-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=564716, encodeId=8f58564e16aa, content=投了第二天就awaiting decision,4天了也不给结果，要拒就快点拒啊，耽误时间的说, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f28b1615792, createdName=bicia, createdTime=Fri Dec 21 00:00:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=)]

2024-11-30 ms2000001750570964 来自广西

审稿速度:3.0
偏重的研究方向：临床试验
经验分享：2024..9.5投 9.10under review
至今还在UR
都说这个杂志速度快
看了一圈没一个人比我久的我都i想催稿了

1 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0 偏重的研究方向：临床试验 经验分享：2024..9.5投 9.10under review 至今还在UR 都说这个杂志速度快 看了一圈没一个人比我久的我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：分享一下我的投稿经历 2020.5.9 submitted to the journal 2020.5.11 under evaluation 2020.5.11 under review 2020.6.7 Awaiting descision 2020.6.11 Major revision 2020.8.10 Revision submitted 2020.8.10 under evaluation 2020.8.13 under review 2020.9.5 Awaiting descision 2020.9.9 Accepted 首次投IJC，投的综述，他们的综述一般是约稿，但是也收散稿，我是提前和编辑部发了邮件自荐的，杂志主编看了后很感兴趣，希望我投稿。审稿人虽然是匿名，但是从comments的言辞之间，让我感觉是其中的一位业界大牛Angelika Amon （Koch Institute MIT）。读了她的意见真是醍醐灌顶，受益良多。所以大修之后基本上改的面目全非，但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床 经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=278, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2200790, encodeId=b1a72200e9029, content=投过3次，第一次18天一审回来，中，快接收时候要实验原始数据第二次under consideration 5天后秒拒第三次 3个月一审回来，中，一开始under consideration 9天后要求改格式并上传实验原始数据，然后才送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b65125344, createdName=146449eem63暂无昵称, createdTime=Sat Apr 27 23:06:31 CST 2024, time=2024-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2180835, encodeId=b19b21808352d, content=求问各位大佬，Under evaluation已经12天了，可以催稿么？着急毕业。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=257, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2029080835, createdName=ms6000000445449810, createdTime=Thu Jan 11 20:03:35 CST 2024, time=2024-01-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=564716, encodeId=8f58564e16aa, content=投了第二天就awaiting decision,4天了也不给结果，要拒就快点拒啊，耽误时间的说, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f28b1615792, createdName=bicia, createdTime=Fri Dec 21 00:00:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=)]

2020-09-17 da-xiang

审稿速度:6.0 | 投稿命中率:25.0
经验分享：分享一下我的投稿经历
2020.5.9 submitted to the journal
2020.5.11 under evaluation
2020.5.11 under review
2020.6.7 Awaiting descision
2020.6.11 Major revision
2020.8.10 Revision submitted
2020.8.10 under evaluation
2020.8.13 under review
2020.9.5 Awaiting descision
2020.9.9 Accepted
首次投IJC，投的综述，他们的综述一般是约稿，但是也收散稿，我是提前和编辑部发了邮件自荐的，杂志主编看了后很感兴趣，希望我投稿。审稿人虽然是匿名，但是从comments的言辞之间，让我感觉是其中的一位业界大牛Angelika Amon （Koch Institute MIT）。读了她的意见真是醍醐灌顶，受益良多。所以大修之后基本上改的面目全非，但是文章的创新型提高好几个层次。

5 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0 偏重的研究方向：临床试验 经验分享：2024..9.5投 9.10under review 至今还在UR 都说这个杂志速度快 看了一圈没一个人比我久的我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：分享一下我的投稿经历 2020.5.9 submitted to the journal 2020.5.11 under evaluation 2020.5.11 under review 2020.6.7 Awaiting descision 2020.6.11 Major revision 2020.8.10 Revision submitted 2020.8.10 under evaluation 2020.8.13 under review 2020.9.5 Awaiting descision 2020.9.9 Accepted 首次投IJC，投的综述，他们的综述一般是约稿，但是也收散稿，我是提前和编辑部发了邮件自荐的，杂志主编看了后很感兴趣，希望我投稿。审稿人虽然是匿名，但是从comments的言辞之间，让我感觉是其中的一位业界大牛Angelika Amon （Koch Institute MIT）。读了她的意见真是醍醐灌顶，受益良多。所以大修之后基本上改的面目全非，但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床 经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=278, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2200790, encodeId=b1a72200e9029, content=投过3次，第一次18天一审回来，中，快接收时候要实验原始数据第二次under consideration 5天后秒拒第三次 3个月一审回来，中，一开始under consideration 9天后要求改格式并上传实验原始数据，然后才送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b65125344, createdName=146449eem63暂无昵称, createdTime=Sat Apr 27 23:06:31 CST 2024, time=2024-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2180835, encodeId=b19b21808352d, content=求问各位大佬，Under evaluation已经12天了，可以催稿么？着急毕业。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=257, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2029080835, createdName=ms6000000445449810, createdTime=Thu Jan 11 20:03:35 CST 2024, time=2024-01-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=564716, encodeId=8f58564e16aa, content=投了第二天就awaiting decision,4天了也不给结果，要拒就快点拒啊，耽误时间的说, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f28b1615792, createdName=bicia, createdTime=Fri Dec 21 00:00:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=)]

2020-09-04 Nevermorx

有没有人投综述呀

197 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0 偏重的研究方向：临床试验 经验分享：2024..9.5投 9.10under review 至今还在UR 都说这个杂志速度快 看了一圈没一个人比我久的我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：分享一下我的投稿经历 2020.5.9 submitted to the journal 2020.5.11 under evaluation 2020.5.11 under review 2020.6.7 Awaiting descision 2020.6.11 Major revision 2020.8.10 Revision submitted 2020.8.10 under evaluation 2020.8.13 under review 2020.9.5 Awaiting descision 2020.9.9 Accepted 首次投IJC，投的综述，他们的综述一般是约稿，但是也收散稿，我是提前和编辑部发了邮件自荐的，杂志主编看了后很感兴趣，希望我投稿。审稿人虽然是匿名，但是从comments的言辞之间，让我感觉是其中的一位业界大牛Angelika Amon （Koch Institute MIT）。读了她的意见真是醍醐灌顶，受益良多。所以大修之后基本上改的面目全非，但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床 经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=278, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2200790, encodeId=b1a72200e9029, content=投过3次，第一次18天一审回来，中，快接收时候要实验原始数据第二次under consideration 5天后秒拒第三次 3个月一审回来，中，一开始under consideration 9天后要求改格式并上传实验原始数据，然后才送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b65125344, createdName=146449eem63暂无昵称, createdTime=Sat Apr 27 23:06:31 CST 2024, time=2024-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2180835, encodeId=b19b21808352d, content=求问各位大佬，Under evaluation已经12天了，可以催稿么？着急毕业。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=257, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2029080835, createdName=ms6000000445449810, createdTime=Thu Jan 11 20:03:35 CST 2024, time=2024-01-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=564716, encodeId=8f58564e16aa, content=投了第二天就awaiting decision,4天了也不给结果，要拒就快点拒啊，耽误时间的说, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f28b1615792, createdName=bicia, createdTime=Fri Dec 21 00:00:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=)]

2021-09-04 凶巴巴恰北北怪兽

7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收编辑很友好

276 18

展开18条回复

[GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0 偏重的研究方向：临床试验 经验分享：2024..9.5投 9.10under review 至今还在UR 都说这个杂志速度快 看了一圈没一个人比我久的我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：分享一下我的投稿经历 2020.5.9 submitted to the journal 2020.5.11 under evaluation 2020.5.11 under review 2020.6.7 Awaiting descision 2020.6.11 Major revision 2020.8.10 Revision submitted 2020.8.10 under evaluation 2020.8.13 under review 2020.9.5 Awaiting descision 2020.9.9 Accepted 首次投IJC，投的综述，他们的综述一般是约稿，但是也收散稿，我是提前和编辑部发了邮件自荐的，杂志主编看了后很感兴趣，希望我投稿。审稿人虽然是匿名，但是从comments的言辞之间，让我感觉是其中的一位业界大牛Angelika Amon （Koch Institute MIT）。读了她的意见真是醍醐灌顶，受益良多。所以大修之后基本上改的面目全非，但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床 经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=278, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2200790, encodeId=b1a72200e9029, content=投过3次，第一次18天一审回来，中，快接收时候要实验原始数据第二次under consideration 5天后秒拒第三次 3个月一审回来，中，一开始under consideration 9天后要求改格式并上传实验原始数据，然后才送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b65125344, createdName=146449eem63暂无昵称, createdTime=Sat Apr 27 23:06:31 CST 2024, time=2024-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2180835, encodeId=b19b21808352d, content=求问各位大佬，Under evaluation已经12天了，可以催稿么？着急毕业。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=257, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2029080835, createdName=ms6000000445449810, createdTime=Thu Jan 11 20:03:35 CST 2024, time=2024-01-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=564716, encodeId=8f58564e16aa, content=投了第二天就awaiting decision,4天了也不给结果，要拒就快点拒啊，耽误时间的说, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f28b1615792, createdName=bicia, createdTime=Fri Dec 21 00:00:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=)]

2022-04-26 ms9000000399989409

偏重的研究方向：肿瘤;Cancer;临床
经验分享：问一下大家under evaluation都持续几天呢?

278 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0 偏重的研究方向：临床试验 经验分享：2024..9.5投 9.10under review 至今还在UR 都说这个杂志速度快 看了一圈没一个人比我久的我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：分享一下我的投稿经历 2020.5.9 submitted to the journal 2020.5.11 under evaluation 2020.5.11 under review 2020.6.7 Awaiting descision 2020.6.11 Major revision 2020.8.10 Revision submitted 2020.8.10 under evaluation 2020.8.13 under review 2020.9.5 Awaiting descision 2020.9.9 Accepted 首次投IJC，投的综述，他们的综述一般是约稿，但是也收散稿，我是提前和编辑部发了邮件自荐的，杂志主编看了后很感兴趣，希望我投稿。审稿人虽然是匿名，但是从comments的言辞之间，让我感觉是其中的一位业界大牛Angelika Amon （Koch Institute MIT）。读了她的意见真是醍醐灌顶，受益良多。所以大修之后基本上改的面目全非，但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床 经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=278, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2200790, encodeId=b1a72200e9029, content=投过3次，第一次18天一审回来，中，快接收时候要实验原始数据第二次under consideration 5天后秒拒第三次 3个月一审回来，中，一开始under consideration 9天后要求改格式并上传实验原始数据，然后才送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b65125344, createdName=146449eem63暂无昵称, createdTime=Sat Apr 27 23:06:31 CST 2024, time=2024-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2180835, encodeId=b19b21808352d, content=求问各位大佬，Under evaluation已经12天了，可以催稿么？着急毕业。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=257, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2029080835, createdName=ms6000000445449810, createdTime=Thu Jan 11 20:03:35 CST 2024, time=2024-01-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=564716, encodeId=8f58564e16aa, content=投了第二天就awaiting decision,4天了也不给结果，要拒就快点拒啊，耽误时间的说, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f28b1615792, createdName=bicia, createdTime=Fri Dec 21 00:00:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=)]

2023-12-29 ms3000001161396804 来自黑龙江省

偏重的研究方向：DNA损伤修复
经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢

265 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0 偏重的研究方向：临床试验 经验分享：2024..9.5投 9.10under review 至今还在UR 都说这个杂志速度快 看了一圈没一个人比我久的我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：分享一下我的投稿经历 2020.5.9 submitted to the journal 2020.5.11 under evaluation 2020.5.11 under review 2020.6.7 Awaiting descision 2020.6.11 Major revision 2020.8.10 Revision submitted 2020.8.10 under evaluation 2020.8.13 under review 2020.9.5 Awaiting descision 2020.9.9 Accepted 首次投IJC，投的综述，他们的综述一般是约稿，但是也收散稿，我是提前和编辑部发了邮件自荐的，杂志主编看了后很感兴趣，希望我投稿。审稿人虽然是匿名，但是从comments的言辞之间，让我感觉是其中的一位业界大牛Angelika Amon （Koch Institute MIT）。读了她的意见真是醍醐灌顶，受益良多。所以大修之后基本上改的面目全非，但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床 经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=278, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2200790, encodeId=b1a72200e9029, content=投过3次，第一次18天一审回来，中，快接收时候要实验原始数据第二次under consideration 5天后秒拒第三次 3个月一审回来，中，一开始under consideration 9天后要求改格式并上传实验原始数据，然后才送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b65125344, createdName=146449eem63暂无昵称, createdTime=Sat Apr 27 23:06:31 CST 2024, time=2024-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2180835, encodeId=b19b21808352d, content=求问各位大佬，Under evaluation已经12天了，可以催稿么？着急毕业。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=257, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2029080835, createdName=ms6000000445449810, createdTime=Thu Jan 11 20:03:35 CST 2024, time=2024-01-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=564716, encodeId=8f58564e16aa, content=投了第二天就awaiting decision,4天了也不给结果，要拒就快点拒啊，耽误时间的说, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f28b1615792, createdName=bicia, createdTime=Fri Dec 21 00:00:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=)]

2024-04-27 146449eem63暂无昵称来自上海

投过3次，第一次18天一审回来，中，快接收时候要实验原始数据第二次under consideration 5天后秒拒第三次 3个月一审回来，中，一开始under consideration 9天后要求改格式并上传实验原始数据，然后才送审

223 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0 偏重的研究方向：临床试验 经验分享：2024..9.5投 9.10under review 至今还在UR 都说这个杂志速度快 看了一圈没一个人比我久的我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：分享一下我的投稿经历 2020.5.9 submitted to the journal 2020.5.11 under evaluation 2020.5.11 under review 2020.6.7 Awaiting descision 2020.6.11 Major revision 2020.8.10 Revision submitted 2020.8.10 under evaluation 2020.8.13 under review 2020.9.5 Awaiting descision 2020.9.9 Accepted 首次投IJC，投的综述，他们的综述一般是约稿，但是也收散稿，我是提前和编辑部发了邮件自荐的，杂志主编看了后很感兴趣，希望我投稿。审稿人虽然是匿名，但是从comments的言辞之间，让我感觉是其中的一位业界大牛Angelika Amon （Koch Institute MIT）。读了她的意见真是醍醐灌顶，受益良多。所以大修之后基本上改的面目全非，但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床 经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=278, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2200790, encodeId=b1a72200e9029, content=投过3次，第一次18天一审回来，中，快接收时候要实验原始数据第二次under consideration 5天后秒拒第三次 3个月一审回来，中，一开始under consideration 9天后要求改格式并上传实验原始数据，然后才送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b65125344, createdName=146449eem63暂无昵称, createdTime=Sat Apr 27 23:06:31 CST 2024, time=2024-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2180835, encodeId=b19b21808352d, content=求问各位大佬，Under evaluation已经12天了，可以催稿么？着急毕业。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=257, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2029080835, createdName=ms6000000445449810, createdTime=Thu Jan 11 20:03:35 CST 2024, time=2024-01-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=564716, encodeId=8f58564e16aa, content=投了第二天就awaiting decision,4天了也不给结果，要拒就快点拒啊，耽误时间的说, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f28b1615792, createdName=bicia, createdTime=Fri Dec 21 00:00:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=)]

2024-01-11 ms6000000445449810 来自北京

求问各位大佬，Under evaluation已经12天了，可以催稿么？着急毕业。。。

257 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0 偏重的研究方向：临床试验 经验分享：2024..9.5投 9.10under review 至今还在UR 都说这个杂志速度快 看了一圈没一个人比我久的我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：分享一下我的投稿经历 2020.5.9 submitted to the journal 2020.5.11 under evaluation 2020.5.11 under review 2020.6.7 Awaiting descision 2020.6.11 Major revision 2020.8.10 Revision submitted 2020.8.10 under evaluation 2020.8.13 under review 2020.9.5 Awaiting descision 2020.9.9 Accepted 首次投IJC，投的综述，他们的综述一般是约稿，但是也收散稿，我是提前和编辑部发了邮件自荐的，杂志主编看了后很感兴趣，希望我投稿。审稿人虽然是匿名，但是从comments的言辞之间，让我感觉是其中的一位业界大牛Angelika Amon （Koch Institute MIT）。读了她的意见真是醍醐灌顶，受益良多。所以大修之后基本上改的面目全非，但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床 经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=278, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2200790, encodeId=b1a72200e9029, content=投过3次，第一次18天一审回来，中，快接收时候要实验原始数据第二次under consideration 5天后秒拒第三次 3个月一审回来，中，一开始under consideration 9天后要求改格式并上传实验原始数据，然后才送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b65125344, createdName=146449eem63暂无昵称, createdTime=Sat Apr 27 23:06:31 CST 2024, time=2024-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2180835, encodeId=b19b21808352d, content=求问各位大佬，Under evaluation已经12天了，可以催稿么？着急毕业。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=257, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2029080835, createdName=ms6000000445449810, createdTime=Thu Jan 11 20:03:35 CST 2024, time=2024-01-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=564716, encodeId=8f58564e16aa, content=投了第二天就awaiting decision,4天了也不给结果，要拒就快点拒啊，耽误时间的说, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f28b1615792, createdName=bicia, createdTime=Fri Dec 21 00:00:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=)]

2018-12-21 bicia

投了第二天就awaiting decision,4天了也不给结果，要拒就快点拒啊，耽误时间的说

327 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2240072, encodeId=aa8822400e23b, content=审稿速度:3.0 偏重的研究方向：临床试验 经验分享：2024..9.5投 9.10under review 至今还在UR 都说这个杂志速度快 看了一圈没一个人比我久的我都i想催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae28218842, createdName=ms2000001750570964, createdTime=Sat Nov 30 15:17:25 CST 2024, time=2024-11-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=886186, encodeId=698588618632, content=审稿速度:6.0 | 投稿命中率:25.0 经验分享：分享一下我的投稿经历 2020.5.9 submitted to the journal 2020.5.11 under evaluation 2020.5.11 under review 2020.6.7 Awaiting descision 2020.6.11 Major revision 2020.8.10 Revision submitted 2020.8.10 under evaluation 2020.8.13 under review 2020.9.5 Awaiting descision 2020.9.9 Accepted 首次投IJC，投的综述，他们的综述一般是约稿，但是也收散稿，我是提前和编辑部发了邮件自荐的，杂志主编看了后很感兴趣，希望我投稿。审稿人虽然是匿名，但是从comments的言辞之间，让我感觉是其中的一位业界大牛Angelika Amon （Koch Institute MIT）。读了她的意见真是醍醐灌顶，受益良多。所以大修之后基本上改的面目全非，但是文章的创新型提高好几个层次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Thu Sep 17 21:55:09 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882727, encodeId=42e4882e2702, content=有没有人投综述呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200927/261b1f9f20d24144bab68b2430f4b774/baaa7e0ae3234a32b652d4b1fd1aa53f.jpg, createdBy=afc55408430, createdName=Nevermorx, createdTime=Fri Sep 04 17:23:50 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014443, encodeId=0aad1014443bf, content=7.14投稿 8.20一审回来，大修 8.24修回，当天外审 8.30under evaluation 9.1awaiting 9.3接收编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=276, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=凶巴巴恰北北怪兽, createdTime=Sat Sep 04 01:30:04 CST 2021, time=2021-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214684, encodeId=d4591214684a7, content=偏重的研究方向：肿瘤;Cancer;临床 经验分享：问一下大家under evaluation都持续几天呢?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=278, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2925481605, createdName=ms9000000399989409, createdTime=Tue Apr 26 19:16:26 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178059, encodeId=9cc621e8059f0, content=偏重的研究方向：DNA损伤修复 经验分享：想问问大家投综述结果怎么样不是约稿的目前review了也会给比较多的意见么还是回来直接拒的那种谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=265, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05565589730, createdName=ms3000001161396804, createdTime=Fri Dec 29 23:19:12 CST 2023, time=2023-12-29, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2200790, encodeId=b1a72200e9029, content=投过3次，第一次18天一审回来，中，快接收时候要实验原始数据第二次under consideration 5天后秒拒第三次 3个月一审回来，中，一开始under consideration 9天后要求改格式并上传实验原始数据，然后才送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b65125344, createdName=146449eem63暂无昵称, createdTime=Sat Apr 27 23:06:31 CST 2024, time=2024-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2180835, encodeId=b19b21808352d, content=求问各位大佬，Under evaluation已经12天了，可以催稿么？着急毕业。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=257, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2029080835, createdName=ms6000000445449810, createdTime=Thu Jan 11 20:03:35 CST 2024, time=2024-01-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=564716, encodeId=8f58564e16aa, content=投了第二天就awaiting decision,4天了也不给结果，要拒就快点拒啊，耽误时间的说, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f28b1615792, createdName=bicia, createdTime=Fri Dec 21 00:00:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241409, encodeId=2384124140980, content=偏重的研究方向：肿瘤;biomarker 经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a00a8248803, createdName=ms5000001852951271, createdTime=Sat Aug 27 21:12:04 CST 2022, time=2022-08-27, status=1, ipAttribution=)]

2022-08-27 ms5000001852951271

偏重的研究方向：肿瘤;biomarker
经验分享：请问各位大佬，我的投稿状态，从under evaluation，变成了awaiting decision，这种情况属于是什么阶段呢？我看评论里都是修改之后才有的awaiting decision，我这个是要被拒了么？还是继续等着呢？

0 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务